Preview

Вопросы современной педиатрии

Расширенный поиск

Современные перевязочные средства в лечении заболеваний кожи

https://doi.org/10.15690/vsp.v19i6.2143

Полный текст:

Аннотация

Повреждением кожного покрова с формированием эрозивно-язвенных дефектов и нарушением кожного барьера сопровождается большое число болезней. Успешная эпителизация дефектов кожи зависит от состояния раневого процесса, компенсаторных функций организма, факторов внешней среды и от правильно подобранного лечения. Комплексное лечение должно включать системные и местные средства терапии, а также современные перевязочные средства. В статье освещены возможности современных перевязочных средств в лечении различных болезней кожи, изложены плюсы и минусы основных современных повязок.

Об авторах

Н. Н. Мурашкин
Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академия Управления делами Президента РФ; НИИ педиатрии и охраны здоровья детей ЦКБ РАН
Россия

Мурашкин Николай Николаевич, доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей, профессор кафедры дерматовенерологии и косметологии ЦГМА, профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1


Конфликт интересов:

Н. Н. Мурашкин — получение исследовательских грантов от фармацевтических компаний Jansen, Eli Lilly, Novartis. Получение гонораров за научное консультирование от компаний Galderma, Pierre Fabre, Bayer, LEO Pharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB.



Р. В. Епишев
Национальный медицинский исследовательский центр здоровья детей
Россия
Москва
Конфликт интересов:

А. И. Материкин, Р. В. Епишев, Э. Т. Амбарчян — получение исследовательских грантов от фармацевтических компаний Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene



А. И. Материкин
Национальный медицинский исследовательский центр здоровья детей
Россия
Москва
Конфликт интересов:

А. И. Материкин, Р. В. Епишев, Э. Т. Амбарчян — получение исследовательских грантов от фармацевтических компаний Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene.



Э. Т. Амбарчян
Национальный медицинский исследовательский центр здоровья детей
Россия
Москва
Конфликт интересов:

А. И. Материкин, Р. В. Епишев, Э. Т. Амбарчян — получение исследовательских грантов от фармацевтических компаний Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene.



Л. А. Опрятин
Национальный медицинский исследовательский центр здоровья детей
Россия
Москва
Конфликт интересов:

Л. А. Опрятин — получение гонораров за научное консультирование от компаний Eli Lilly, Jansen



Р. А. Иванов
Национальный медицинский исследовательский центр здоровья детей
Россия
Москва
Конфликт интересов:

Р. А. Иванов подтвердил отсутствие конфликта интересов, о котором необходимо сообщить



Список литературы

1. Snyder D, Sullivan N, Margolis D, Schoelles K. Skin Substitutes for Treating Chronic Wounds. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.

2. Childs DR, Murthy AS. Overview of Wound Healing and Management. Surg Clin North Am. 2017;97(1):189–207. doi: 10.1016/j.suc.2016.08.013.

3. de Smet GHJ, Kroese LF, Menon AG, et al. Oxygen therapies and their effects on wound healing. Wound Repair Regen. 2017; 25(4):591–608. doi: 10.1111/wrr.12561.

4. Gantwerker EA, Hom DB. Skin: histology and physiology of wound healing. Facial Plast Surg Clin North Am. 2011;19(3): 441–453. doi: 10.1016/j.fsc.2011.06.009.

5. Korber A, Klode J, Al-Benna S, et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges. 2011;9(2):116–121. doi: 10.1111/j.1610-0387.2010.07535.x.

6. Shanmugam VK, Schilling A, Germinario A, et al. Prevalence of immune disease in patients with wounds presenting to a tertiary wound healing centre. Int Wound J. 2012:9(4):403–411. doi: 10.1111/j.1742-481X.2011.00899.x.

7. Rekha PD, Rao SS, Sahana TG, Prabhu A. Diabetic wound management. Br J Community Nurs. 2018;23(Sup9):S16–S22. doi: 10.12968/bjcn.2018.23.Sup9.S16.

8. Hart DW, Wolf SE, Chinkes DL, et al. Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn. J Trauma. 2003;54(4):755–764. doi: 10.1097/01.TA.0000060260.61478.A7.

9. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed prepa ration: A systematic approach to wound management. Wound Repair Regen. 2003;11(Suppl 1):S1–S28. doi: 10.1046/j.1524-475x.11.s2.1.x.

10. White R, Cutting KF. Modern exudate management: A review of wound treatments. World Wide Wounds. 2006. Available online: http://www.worldwidewounds.com/2006/september/White/Modern-Exudate-Mgt.html. Accessed on August 17, 2020.

11. Paul J. Characteristics of chronic wounds that itch. Adv Skin Wound Care. 2013;26:320–332. doi: 10.1097/01.ASW.0000431203.64591.2f.

12. Zakhary SA. The Development and Content Validation of a Multidisciplinary, Evidence-based Wound Infection Prevention and Treatment Guideline. Ostomy Wound Manage. 2017;63(11):18–29.

13. Jones SA, Bowler PG, Walker M, Parsons D. Controlling wound bioburden with a novel silver-containing Hydrofiber® dressing. Wound Repair Regen. 2004;12(3):288–294. 10.1111/j.1067-1927.2004.012304.x.

14. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med. 2002;34(6):419–427. doi: 10.1080/078538902321012360.

15. Gardner SE, Haleem A, Jao Y-L, et al. Cultures of diabetic foot ulcers without clinical signs of infection do not predict outcomes. Diabetes Care. 2014;37(10):2693–2701. doi: 10.2337/dc14-0051.

16. International Wound Infection Institute (IWII). Wound Infection in Clinical Practice. Wounds International. November 11, 2016. Available online: https://www.woundsinternational.com/download/resource/6003. Accessed on August 17, 2020.

17. World Union of Wound Healing Societies (WUWHS), Florence Congress, Position Document. Management of Biofilm. Wounds International. September 23, 2016. Available online: https://www.woundsinternational.com/download/resource/5926. Accessed on August 17, 2020.

18. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008;16(1):37–44. doi: 10.1111/j.1524-475X.2007.00321.x.

19. Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 29–32. doi: 10.33667/2078-5631-2019-1-7(382)-29-32.

20. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. doi: 10.1038/nrdp.2016.82.

21. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302–309. doi: 10.1038/cmi.2012.15.

22. Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76. doi: 10.1016/j.jaci.2017.01.011.

23. Baharestani MM. Pressure ulcers in special populations: neonates and pediatrics. In: Baranoski S, Ayello E, eds. Wound Care Essentials: Practice Principles. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.

24. Suraseranivongse S, Kaosaard R, Intakong P. A comparison of postoperative pain scales in neonates. Br J Anaesth. 2006; 97(4):540–544. doi: 10.1093/bja/ael184.

25. Irving V, Bethell E, Burton F. Neonatal wound care: minimizing trauma and pain. Wounds UK. 2006;2(1):33–41.

26. Baharestani MM, Pope E. Chronic wounds in neonates and children. In: Krasner D, Rodeheaver GT, Sibbald GT, eds. Chronic Wound Care: A Clinical Source Book for Healthcare Professionals. 4th ed. Malvern, PA: HMP Communications; 2007. pp. 679–693.

27. Hollinworth H, Collier M. Nurses’ views about pain and trauma at dressing changes: results of a national survey. J Wound Care. 2000;9(8):369–373. doi: 10.12968/jowc.2000.9.8.26282.

28. White R. A Multinational survey of the assessment of pain when removing dressings. Wounds UK. 2008;4(1).

29. Schumann H, Beljan G, Hoping D, Bruckner-Tuderman L. Atraumatic dressings in fragile skin conditions: use of the soft silicone dressing (Mepilex) in hereditary and acquired bullous skin disease. Poster presentation. EWMA; 2005.

30. Butcher M, White R. Quantifying the financial impact of pain at dressing change. In: Upton D, ed. Psychological impact of pain in patients with wounds. Wounds UK; 2011. pp. 52–77.

31. Davies P, Rippon M. Evidence review: the clinical benefits of Safetac technology in wound care. J Wound Care. 2008;Suppl:3–31.

32. Jones J, Williams H. Wound management should not be a pain. Br J Community Nurs. 2017;22(Sup9):S38–S46. doi: 10.12968/bjcn.2017.22.Sup9.S38.

33. Fauziyah H, Gayatri D. Pain, stress, and sleep quality in chronic wound patients. Enferm Clin. 2018;28(Suppl 1):176–179. doi: 10.1016/S1130-8621(18)30062-7.

34. Morgan D. Wounds — what should a dressings formulary include? Hospital Pharmacist. 2002;9(9):262–266.

35. Edwards-Jones V. Antimicrobial and barrier effects of silver against methicillin-resistant. Staphylococcus aureus. J Wound Care. 2006;15(7):285–290. doi: 10.12968/jowc.2006.15.7.26951.

36. Leaper DJ. Silver dressings: their role in wound management. Int Wound J. 2006;3(4):282–294. doi: 10.1111/j.1742-481X.2006.00265.x.

37. Bjarnsholt T, Kirketerp-Moller K, Kristiansen S, et al. Silver against Pseudomonas aeruginosa biofilms. APMIS. 2007;115(8):921–928. doi: 10.1111/j.1600-0463.2007.apm_646.x.

38. Castellano JJ, Shafii SM, Ko F, et al. Comparative evaluation of silvercontaining antimicrobial dressings and drugs. Int Wound J. 2007;4(2):114–122. doi: 10.1111/j.1742-481X.2007.00316.x.

39. Cutting K, White R, Edmonds M. The safety and efficacy of dressings with silver — addressing clinical concerns. Int Wound J. 2007;4(2):177–184. doi: 10.1111/j.1742-481X.2007.00338.x.

40. Barrett S. Mepilex® Ag: an antimicrobial, absorbent foam dressing with Safetac® technology. Br J Nurs. 2009;18(Sup7): S28–S36. doi: 10.12968/bjon.2009.18.Sup7.45133.

41. Koerner S, Adams D. Use of a soft silicone silver transfer dressing (SSSTD) under compression may manage biofilm and exudate while promoting patient comfort. Poster presentation at the 47th Annual Conference of the Wound Ostomy and Continence Nurses Society, San Antonio, TX, US, 2015.

42. McCarty S, Davies P, Rippon M. Mepilex Border Ag: an in-market evaluation. Poster presentation at the Wounds UK Conference, Harrogate, UK, 2013.

43. Chadwick P, Taherinejad F, Hamberg K, et al. Clinical and scientific data on a silver-containing soft-silicone foam dressing: an overview. J Wound Care. 2009;18(11):486–490. doi: 10.12968/jowc.2009.18.11.45001.

44. Bibic A, Hamberg K. Antimicrobial effect of a new silver-containing soft silicone exudate transfer dressing against common wound pathogens in vitro. Poster presentation at the Symposium on Advanced Wound Care and Wound Healing Society, Orlando, FL, US, 2014.

45. Werthen M, Taherinejad F, Gerner E. In vitro study of silvercontaining wound dressings — adhesion, fluid handling and antimicrobial effect. Poster presentation at the European Wound Management Association Conference, Vienna, Austria, 2012.

46. Lo SF, Chang CJ, Hu WY, et al. The effectiveness of silverreleasing dressings in the management of non-healing chronic wounds: a meta-analysis. J Clin Nurs. 2009;18(5):716–728. doi: 10.1111/j.1365-2702.2008.02534.x.

47. Carter MJ, Tingley-Kelley K, Warriner RA III. Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis. J Am Acad Dermatol. 2010;63(4):668–679. doi: 10.1016/j.jaad.2009.09.007.

48. Leaper D, Munter C, Meaume S, et al. The use of Biatain Ag in hard-to-heal venous leg ulcers: meta-analysis of randomised controlled trials. PLoS One. 2013;8(7):e67083. doi: 10.1371/journal.pone.0067083.

49. Mellerio JE. Infection and colonization in epidermolysis bullosa. Dermatol Clin. 2010;28(2):267–269. doi: 10.1016/j.det.2010.01.004.

50. Буллезный эпидермолиз: руководство для врачей / под ред. Н.Н. Мурашкина, Л.С. Намазовой-Барановой. — М.: ПедиатрЪ; 2019. — 444 с.

51. International Consensus. Appropriate Use of Silver Dressings in Wounds. An Expert Working Group Consensus. London: Wounds International; 2012. Available online: https://www.woundsinternational.com/download/resource/6010. Accessed on August 17, 2020.

52. Best Practice Statement. The use of topical antiseptic/antimicrobial agents in wound management. 2nd ed. Wounds UK; 2011.

53. Mir G. Diabetic foot ulcer healing with a silver dressing combined with soft silicone technology. Wounds International. 2013;4(3): 15–18. Available online: https://www.woundsinternational.com/download/resource/6828. Accessed on: August 17, 2020.

54. Barrows C. Enhancing patient outcomes — reducing the bottom line: the use of antimicrobial soft silicone foam dressing in home health. Home Healthc Nurse. 2009; 27(5): 279–284. doi: 10.1097/01.nhh.0000356778.78126.4d.

55. Silverstein P, Heimbach D, Meites H, et al. An open, parallel, randomized, comparative, multicenter study to evaluate the costeffectiveness, performance, tolerance, and safety of a silver-containing soft silicone foam dressing (intervention) vs silver sulfadiazine cream. J Burn Care Res. 2011;32(6):617–626. doi: 10.1097/BCR.0b013e318236fe31.

56. Schumann H, Apelqvist J, Schmidtchen, A et al. Open, noncomparative, multicentre investigation exploring the tolerance of an absorbent foam dressing containing silver used in chronic wounds. Poster presentation at the European Wound Management Association Conference, Glasgow, UK, 2007.

57. Kheng DE. Evaluation of Mepilex Ag, a silver impregnated soft silicone absorbent dressing in patients with critically colonized venous leg ulcers — 5 case reviews. Poster presentation at the 3rd Congress of the World Union of Wound Healing Societies, Toronto, Canada, 2008.

58. Tong JW. Case reports on the use of antimicrobial (silver impregnated) soft silicone foam dressing on infected diabetic foot ulcers. Int Wound J. 2009;6(4):275–284. doi: 10.1111/j.1742-481X.2009.00610.x.

59. Bello YM, Falabella AF, Schachner LA. Management of epidermolysis bullosa in infants and children. Clin Dermatol. 2003;21(4): 278–282. doi: 10.1016/s0738-081x(03)00050-6.

60. Denyer J. Management of severe blistering disorders. Semin Neonatol. 2000;5(4):321–324. doi: 10.1053/siny.2000.0017.

61. Ly L, Su JC. Dressings used in epidermolysis bullosa blister wounds: a review. J Wound Care. 2008;17(11):482–492. doi: 10.12968/jowc.2008.17.11.31476.

62. Meola S. Epydermolysis bullosa: a new technique for mask ventilation. Paediatr Anaesth. 2008;18(11):1109–1111. doi: 10.1111/j.1460-9592.2008.02594.x.

63. Schober-Flores C. Epidermolysis bullosa. Wound care pearls for the non-infected and infected wound. J Dermatol Nurs Assoc. 2009;1(1); 21–28. doi: 10.1097/JDN.0b013e3181977521.

64. Lara-Corrales I, Arbuckle A, Zarinehbaf S, Pope E. Principles of wound care in patients with epidermolysis bullosa. Pediatr Dermatol. 2010;27(3):229–237. doi: 10.1111/j.1525-1470.2010.01086.x.

65. Denyer J, Foster L. Use of a transparent porous dressing coated on the wound contact side with soft silicone (Mepitel One) in the management of children with epidermolysis bullosa. Poster presentation at Wounds UK Conference, Harrogate, United Kingdom, 2010.

66. Waring M, Rippon M, Bielfeldt S, et al. Cell attachment to adhesive dressings: qualitative and quantitative analysis. Wounds UK. 2008;4(3):35–47.

67. Denyer J, Pillay E, Clapham J. Best practice guidelines for skin and wound care in epidermolysis bullosa. International Consensus. Wounds International; 2017.

68. Gotschall CS, Morrison MI, Eichelberger MR. Prospective, randomized study of the efficacy of Mepitel® on children with partialthickness scalds. J Burn Care Rehab. 1998;19(4):279–283. doi: 10.1097/00004630-199807000-00002.

69. Barrett S. Management of traumatic wounds with Mepitel One: a case study evaluation. Poster presentation at Wounds UK Conference, Harrogate, United Kingdom, 2010.

70. Sanchez FJG. Evaluation; first experiences of a new one-sided selffixating wound contact layer. Poster presentation at the European Wound Management Association Conference, Geneva, Switzerland, 2010.

71. Acton C. Use of Mepitel One in conjunction with negative pressure wound therapy: a case study series. Poster presentation at Wounds UK conference, Harrogate, United Kingdom, 2010.

72. Collin O. Use of Mepitel One dressing following hand surgery: a case study series. Poster presentation at the Australian Wound Management Conference, Perth, Australia, 2010.

73. Whalley A. Case study evaluations of Mepitel One in the management of wounds of patients with diabetes. Poster presentation at Wounds UK Conference, Harrogate, United Kingdom, 2010.

74. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X.

75. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.

76. He H, Koh MJ-A, Lee HY, Ang SB. Pilot study of a customized nanotextile wet garment treatment on moderate and severe atopic dermatitis: A randomized clinical trial. Pediatr Dermatol. 2020;37(1):52–57. doi: 10.1111/pde.13981.

77. Cadmus SD, Sebastian KR, Warren D, et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study. Pediatr Dermatol. 2019;36(4):437–441. doi: 10.1111/pde.13830.

78. Nicol NH, Boguniewicz M. Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis. Immunol Allergy Clin North Am. 2017; 37(1):123–139. doi: 10.1016/j.iac.2016.08.003.

79. Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-Lopez JJ. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(3):688–695. doi: 10.1111/bjd.15165.

80. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70(2):338–351. doi: 10.1016/j.jaad.2013.10.010.

81. Georgesen C, Wildman H, Wang X, Magro C. Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: A treatment approach. Dermatol Online J. 2017;23(11):13030/qt9787b6c0.

82. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de psoriase 2012. Guias de avaliacao e tratamento. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2012.

83. Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662. doi: 10.1016/j.jaad.2009.05.048.

84. Andersen RM, Thyssen JP, Maibach HI. The role of wet wrap therapy in skin disorders — a literature review. Acta Derm Venereol. 2015;95(8):933–939. doi: 10.2340/00015555-2134.

85. Devillers AC, Oranje AP. Efficacy and safety of wet-wrap dressings as an intervention treatment in children with severe and/ or refractory atopic dermatitis: a critical review of literature. Br J Dermatol. 2006;154(4):579–585. doi: 10.1111/j.1365-2133.2006.07157.x.


Для цитирования:


Мурашкин Н.Н., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Опрятин Л.А., Иванов Р.А. Современные перевязочные средства в лечении заболеваний кожи. Вопросы современной педиатрии. 2020;19(6):420-431. https://doi.org/10.15690/vsp.v19i6.2143

For citation:


Murashkin N.N., Epishev R.V., Materikin A.I., Ambarchian E.T., Opryatin L.A., Ivanov R.A. Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”. Current Pediatrics. 2020;19(6):420-431. (In Russ.) https://doi.org/10.15690/vsp.v19i6.2143

Просмотров: 278


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)